Both these chemotherapies decreased the frequency (%) of MDSCs (HLA-DR+CD11b+CD33+) compared to the pre-treatment and that the combination of CIK and chemotherapy was associated with increased survival of metastatic renal cell carcinoma and pancreatic cancer patients compared to CIK alone treated patients [14]. The gene discussed is ITGAM; the disease is familial pancreatic carcinoma.